Oveporexton

Oveporexton
Clinical data
Other names	TAK-861; TAK861
Routes of; administration	Oral
Drug class	Orexin OX2 receptor agonist
Identifiers
	IUPAC name N-[(2S,3R)-2-[[3-(3,5-difluorophenyl)-2-fluorophenyl]methyl]-4,4-difluoro-1-(2-hydroxy-2-methylpropanoyl)pyrrolidin-3-yl]ethanesulfonamide;
CAS Number	2460722-04-5;
PubChem CID	154617563;
Chemical and physical data
Formula	C23H25F5N2O4S
Molar mass	520.52 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCS(=O)(=O)N[C@@H]1[C@@H](N(CC1(F)F)C(=O)C(C)(C)O)CC2=C(C(=CC=C2)C3=CC(=CC(=C3)F)F)F;
	InChI InChI=1S/C23H25F5N2O4S/c1-4-35(33,34)29-20-18(30(12-23(20,27)28)21(31)22(2,3)32)10-13-6-5-7-17(19(13)26)14-8-15(24)11-16(25)9-14/h5-9,11,18,20,29,32H,4,10,12H2,1-3H3/t18-,20+/m0/s1; Key:KVMGAIOTUIGROS-AZUAARDMSA-N;

Oveporexton (INNTooltip International Nonproprietary Name; developmental code name TAK-861) is an orexin receptor agonist which is under development for the treatment of narcolepsy and idiopathic hypersomnia. It is taken by mouth. The drug is a selective orexin OX₂ receptor agonist. It has wakefulness-promoting effects in monkeys and rodents. Oveporexton is being developed by Takeda. As of December 2024, it is in phase 3 clinical trials.

Clinical data

Other names	TAK-861; TAK861
Routes of administration	Oral
Drug class	Orexin OX₂ receptor agonist
Identifiers
IUPAC name N-[(2S,3R)-2-[[3-(3,5-difluorophenyl)-2-fluorophenyl]methyl]-4,4-difluoro-1-(2-hydroxy-2-methylpropanoyl)pyrrolidin-3-yl]ethanesulfonamide
CAS Number	2460722-04-5
PubChem CID	154617563
Chemical and physical data
Formula	C₂₃H₂₅F₅N₂O₄S
Molar mass	520.52 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES CCS(=O)(=O)N[C@@H]1[C@@H](N(CC1(F)F)C(=O)C(C)(C)O)CC2=C(C(=CC=C2)C3=CC(=CC(=C3)F)F)F
InChI InChI=1S/C23H25F5N2O4S/c1-4-35(33,34)29-20-18(30(12-23(20,27)28)21(31)22(2,3)32)10-13-6-5-7-17(19(13)26)14-8-15(24)11-16(25)9-14/h5-9,11,18,20,29,32H,4,10,12H2,1-3H3/t18-,20+/m0/s1 Key:KVMGAIOTUIGROS-AZUAARDMSA-N